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Background. To compare the efficacy and safety of a new ocular insert versus conventional mydriasis in cataract surgery.Methods.
We selected 70 patients undergoing cataract surgery. Thirty five patients (Group 1) received instillation of mydriatic drops
(tropicamide 1%, phenylephrine 10%, and cyclopentolate 1%) prior to surgery, and 35 patients (Group 2) had a Mydriasert insert
(The´a Pharma) (0.28mg of tropicamide and 5.4mg of phenylephrine hydrochloride) placed in the inferior fornix. Pupil size before
and after surgery, blood pressure, and heart rate were measured. Results. Before surgery, pupil diameter was 9.44 ± 1.17mm in
Group 1 and 9.05 ± 1.54 in Group 2 (𝑃 > 0.05). Twenty four hours after surgery, pupil diameter was 5.20 ± 1.54mm in Group 1
and 3.33 ± 1.15 in Group 2 (𝑃 < 0.001). There were no statistically significant differences in blood pressure or heart rate between
groups. Conclusions. The effect of the Mydriasert insert was similar to conventional mydriatic agents. Pupil size was restored to
normal faster when using the Mydriasert insert compared with conventional mydriatic agents for pupil dilation.
1. Introduction
Pharmacologic mydriasis can be induced by an adrenergic
stimulant such as phenylephrine, which acts on the dilator
musculature of the iris, or by an acetylcholine antagonist such
as tropicamide, which allows for relaxation of the sphincter.
These topical agents, however, cause nonocular reactions:
for example, dry mouth, tachycardia, headache, and allergic
reactions have been reported with the use of tropicamide.
Phenylephrine is an alpha-receptor adrenergic agonist used
locally for ocular disorders because of its vasoconstrictor
and mydriatic actions. Cardiovascular reactions occur with
phenylephrine, primarily in elderly patients, and include
a marked increase in blood pressure, syncope, myocardial
infarction, tachycardia, and arrhythmia [1, 2].
Mydriasert (The´a Pharma), developed to induce preoper-
ative mydriasis, is an ophthalmic insert that contains 0.28mg
of tropicamide and 5.4mg of phenylephrine hydrochloride.
It is an insoluble minimatrix coated with a semipermeable
membrane that increases local tolerance and regulates the
release rate of the active ingredients [3].
Mydriasert is placed in the inferior conjunctival fornix 60
minutes prior to surgery.
The purpose of this study was to evaluate the efficacy and
cardiovascular safety of this new ophthalmic insert compared
with the standard preoperative mydriatic agents in cataract
surgery.
2. Methods
The Ethics Committee for Clinical Investigation of Aragon
(CEICA) approved the study design. All of the participants
provided written informed consent, and the study method-
ology followed the guidelines of the Helsinki Declaration. A
total of 75 eyes of 75 consecutive subjects whowere scheduled
for routine cataract surgery were prospectively enrolled. We
wanted to show the reality of routine cataract surgery, so
we did not exclude any type of cataract. Any allergy to
mydriatic agents was the only exclusion criterion. Three of
the subjects did not provide informed consent, and two did
not complete the tests included in the exploration protocol.
Therefore, 70 eyes of white European-origin subjects were
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Table 1: Clinical characteristics of both study groups.
Group 1: Drops Group 2: Mydriasert 𝑃
Age (years) 75.53 75.44 0.969
Female 55.6% 67.9% 0.317
Arterial hypertension 50% 50% 1
IDDM 14.7% 10% 0.212
NIDDM 11.8% 14.8% 0.726
Pseudoexfoliation 2.8% 15.4% 0.072
Alpha-antagonist use 6.5% 3.8% 0.661
N 35 35
IDDM: insulin-dependent diabetes mellitus; NIDDM: noninsulin-dependent diabetes mellitus; N: number of subjects; 𝑃: statistical significance level (𝑃 <
0.005).
included in the statistical analysis. When both eyes fulfilled
the inclusion criteria, only one eye per subject was randomly
selected. Patients were randomized into two groups. Group
1 received the standard practice of instillation of mydriatic
drops: a combination of tropicamide 1%, phenylephrine 10%,
and cyclopentolate 1% was instilled at 15-minute intervals for
1 hour preoperatively. In Group 2, the Mydriasert insert was
placed in the lower fornix 1 hour and removed before the
surgery by the nurse. Three senior surgeons performed all of
the procedures and were blind to the dilation treatment.
All operationswere done under topical anaesthesia (tetra-
caine 0.1% and oxybuprocaine 0.4%), and no miotic agents
were used at the surgery.
Pupil measurements were performed using the Palomar
pupillometer, by a masked observer, and the light intensity
was the same throughout all procedures. Blood pressure and
heart rate were measured every 15 minutes 4 times after
beginning the dilatation procedure, and pupil photographs
were taken before and after surgery. Patient characteristics
and comorbidities (arterial hypertension, diabetes mellitus,
alpha-antagonist treatment, and pseudoexfoliation) were
noted in the preoperative assessment.
Statistical Analysis. All statistical analyses were calculated
using IBM SPSS (version 19.0; IBM Corporation, Somers,
NY) statistical software. All of the variables studied followed
a normal distribution as verified with the Kolmogorov-
Smirnov test (K-S of 1 sample). Patient characteristics were
compared between groups using the Chi-square test. Pupil
size, blood pressure, and heart rate were analyzed using a t-
test.
3. Results
Table 1 shows the patient characteristics and comorbidities
of both groups. There were no differences between groups
(𝑃 > 0.005, Chi-square test) in age, female (%), arterial
hypertension, insulin-dependent diabetes mellitus (IDDM),
noninsulin-dependent diabetes mellitus (NIDDM), pseu-
doexfoliation, or alpha-antagonist use.
Table 2 shows the pupil diameter at each time point in
both groups. Fifteen minutes after starting treatment, pupil
dilation in Group 1 (drops) was 5.78 ± 1.86 and that in Group
2 was 4.64 ± 1.49mm (𝑃 = 0.011, t-test). There were no
statistically significant differences in the other measurements
between groups except for pupil size 24 hours after surgery
(pupil diameter 5.20 ± 1.54mm in Group 1 and 3.33 ±
1.15mm in Group 2 (𝑃 < 0.001)).
No differences were found about the pupil size just before
or after cataract surgery among the two groups. However,
intraoperative data were not recorded. No other methods
(pharmacological ormechanical) for pupil dilation were used
during the surgeries.
Table 3 shows the blood pressure and heart rate mea-
surements. No significant differences were detected between
groups at any time (𝑃 > 0.05, t-test).
Surgery complications were collected (posterior capsule
rupture, flaccid iris, and iris herniation) and were considered
homogenous between groups (𝑃 > 0.05, analysis of variance
[ANOVA]). No patient was unable to tolerate the insert.
4. Discussion
Our findings indicated that the Mydriasert insert achieves
good pupil dilatation before cataract surgery, comparable
to the standard set of preoperative mydriatic agents. At 15
minutes after beginning the pupil dilation treatment, pupil
size was greater in patients receiving instillation of mydriatic
drops (Group 1, 5.78 ± 1.86mm) than in those treated
with the Mydriasert insert (Group 2, 4.64 ± 1.49mm).
This finding was expected because the ophthalmic insert
gradually releases the two active ingredients, phenylephrine
and tropicamide, and at least 1 hour is needed to reach
maximum pupil dilatation [4, 5].
One limitation of this study is that we used one additional
topical drug inGroup 1 (cyclopentolate) as long asMydriasert
only contains tropicamide and phenylephrine. We did not
change our standard set of mydriatic drops in purpose to
reproduce the habitual conditions of preoperative cataract
patients. However, the fact that therewere no statistical differ-
ences in preoperative dilatation, with or without cyclopento-
late, allows us to recommend eliminating the use of this drug
preoperatively.
The pupil returned to its normal size more quickly in
patients using the Mydriasert insert than in those using topi-
cal drops. Installing cyclopentolate, it is known that the pupil
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Table 2: Pupil diameter (mm).
Group 1: Drops Group 2: Mydriasert
Mean SD Mean SD 𝑃
15 minutes 5.78 1.86 4.64 1.49 0.011
30 minutes 7.83 1.69 7.67 2.44 0.75
45 minutes 8.71 1.68 9 1.75 0.564
60 minutes (presurg) 9.44 1.17 9.05 1.54 0.481
End of surgery 6.73 1.51 6.72 0.82 0.99
24 hours postop 5.20 1.54 3.33 1.15 <0.001
𝑁 35 35
SD: standard deviation; presurg: presurgical; postop: postoperative;𝑁: number of subjects; 𝑃: statistical significance level (𝑃 < 0.005).
Table 3: Blood pressure and heart rate in both groups during the study.
Group 1: Drops Group 2: Mydriasert
Mean SD Mean SD 𝑃
HR 15min. (bpm) 66.77 10.09 71.21 10.89 0.099
HR 30min. (bpm) 65.83 10.34 68.44 11.09 0.34
HR 45min. (bpm) 66.70 10.0 71.0 10.95 0.18
HR postop (bpm) 66.81 9.94 70.55 11.52 0.23
SBP 15min. 133.69 26.5 134.81 25.7 0.86
SBP 30min. 126.34 22.97 132.11 25.10 0.35
SBP 45min. 125.48 16.93 127.80 17.95 0.66
SBP postop 138.26 28.02 143.55 24.16 0.48
DBP 15min. 69.66 13.78 71.07 10.88 0.66
DBP 30min. 67.89 11.59 69.44 10.09 0.58
DBP 45min. 67.65 10.59 70.50 11.58 0.40
DBP postop 66.85 11.10 72.55 8.19 0.60
𝑁 35 35
HR: heart rate; bpm: beats per minute; postop: postoperative; SBP: systolic blood pressure; postop: postoperative; DBP: diastolic blood pressure;𝑁: number of
subjects; SD: standard deviation; P: statistical significance level (𝑃 < 0.005).
needs 24 hours to return to normal size. Due to the long-
acting effects of this drug, the pupil often remains dilated,
and vision is blurred until the day after cataract surgery. The
effects of the Mydriasert insert, however, disappear within a
few hours.
TheMydriasert insert, with a small oblong cylinder shape,
is insoluble, sterile, and biocompatible. It is inserted into the
inferior conjunctival sac following instillation of one drop
of anesthetic. Another advantage of the insert is that this
method requires only two simple maneuvers, one to insert
and one to withdraw the device, thus reducing patients’
discomfort and saving time for the nursing staff, compared
to having to administer drops to patients every 15 minutes. In
all cases, the nurses were able to retrieve the device, and no
history of ocular discomfort or ocular irritationwas reported.
The blood pressure and heart rate measurements did
not differ significantly between groups. These results are
consistent with those of Morgado et al. [6] and might be due
to difficulties in determining the actual cause of increased
blood pressure during surgery.
Systemically administered phenylephrine, a powerful 𝛼-
adrenergic receptor agonist, leads to peripheral vasocon-
striction, resulting in increased systolic and diastolic blood
pressure. Topical phenylephrine 10% increases blood pressure
by up to 10mmHg in 2%of subjects [7]. Absorption across the
conjunctiva and nasalmucosa avoids first-passmetabolism in
the liver and results in peak levels only 10minutes after topical
administration [8]. Nevertheless, reports of side effects in the
adult population are rare in view of its widespread use.
Additional benefits may include that, during the study
period, the nursing staff found application of Mydriaert a
simple, efficient, and one-off event, saving time in a busy
cataract unit.
In summary, the effects of the Mydriasert insert are
comparable to those of standard mydriatic eyedrops in terms
of cardiac safety and pupil dilation, and recovery of the
normal pupil size is fast. Therefore, Mydriasert is a good
alternative option for pupillary dilation prior to cataract
surgery.
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